The Healthcare Businesswomen’s Association will honor the recipient at an event later this year in New York City.
Dr. Yvonne Greenstreet is the 2024 Healthcare Businesswomen’s Association (HBA) Woman of the Year.
Greenstreet is the CEO of Alnylam, a pharmaceutical company focused on developing RNA interference therapeutics. The HBA also named Dr. Otis Johnson as its honorable mentor of the year, and awarded Dr. Katherine Schoenborn its annual STAR honor.
The HBA will honor Greenstreet at its annual Woman of the Year event, which will take place on May 10 in New York City. The event will also be broadcast for remote attendees across the globe.
In a press release shared with Pharmaceutical Executive, HBA CEO Mary Stutts said, “The HBA is proud to recognize and showcase this year’s award recipients for their notable and remarkable commitment and valuable contributions to women in the healthcare ecosystem. These three outstanding individuals are trailblazers, advocates, and true leaders in their respective careers and are clearly deserving of respect, admiration, and appreciation from all of us at the global HBA and throughout the industry.”
The press release explains that Greenstreet earned the honor due to her work as a leader in the pharmaceutical industry. As CEO, she has helped Alnylam earn recognition, such as being named as one of Fortune’s best workplaces for women. The company is also named as one of America’s most responsible companies by Newsweek, among other honors.
Greenstreet is a member of the board of directors for The American Funds, along with being a member of the Bill and Melinda Gates Foundation Scientific Advisory Committee.
The HBA’s honorable mentor of the year, Dr. Otis Johnson, is a co-founder and principal consultant at Trial Equity. Each year, the HBA grants the title of mentor of the year to a member of the industry who has shown themselves to be an ally by advancing, promoting, and mentoring women in the industry.
Johnson previously worked as the chief diversity, equity, inclusion, and sustainability officer at Clario. During his time there, his work helped elevate the company’s EcoVadis status. His achievements in the role include advancing pay equity and improving the balance of gender in leadership roles.
As an advisory member of the HBA’s global advisory board, Johnson is credited with amplifying underrepresented voices.
The HBA’s 2023 Strategic Transformation Achievement Recognition (STAR) volunteer recipient, Dr. Katherine Schoenborn, is the chair emerita of HBA Europe. Schoenborn earned the honor for her work in various HBA leadership roles, during which she has co-founded and lead various chapters and branches of the HBA across Europe.
(Jan. 9, 2024); HBA; 2024 Woman of the Year Yvonne Greenstreet; https://hbanet.org/our-impact/hba-awards/hba-woman-year/2024-woman-year-yvonne-greenstreet
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.